BBS-Bioactive Bone Substitutes Plc

Financial calendar and Annual General Meeting in 2024

BBS-Bioactive Bone Substitutes, Company announcement, 27 December 2023 at 5:00 p.m.

Financial calendar and Annual General Meeting in 2024

During the year 2024, BBS-Bioactive Bone Substitutes Plc (”BBS”) will publish the financial information as follows:

Financial Statements Release for the year 2023 will be published on Monday 26 February 2024 at 9.00 a.m.
Half-year financial report January-June 2024 will be published on Friday 30 August 2024
The Annual Report for the year 2023 will be published during the week 13/2024 the latest.

The Annual General Meeting is planned to be held on Tuesday 30 April 2024. Company’s Board of Directors will convene the meeting at a later date.

BBS-Bioactive Bone Substitutes Plc

Juliusz Rakowski, CEO

For more information, please contact:

Juliusz Rakowski, CEO
[phone]
[e-mail]

Certified Advisor:

Nordic Certified Adviser AB,
[phone],
[e-mail]

BBS in brief

BBS -Bioactive Bone Substitutes Plc is a orthobiology company that started its operations in 2003. We have developed a new product for the treatment of complex bone fractures and bone healing issues. Our goal is to provide next-generation medical products for the treatment of bone injuries in orthopedic surgery. In the pharmaceutical industry, the development and research work require perseverance and courage to innovate. We have a track record of over 20 years in this field. Our company is characterized by expertise, innovation, and dedicated employees who are passionate about their work. Our first developed product, ARTEBONE Paste, is in the final stages of the CE marking process to enable its commercialization in the EU market. We are based in Oulu with a medical manufacturing facility in Reisjärvi, holding a manufacturing license. The company's headquarters are in Oulu, and we employ over 20 people.

BBS has been listed on Nasdaq First North Growth Market Finland since February 2018.

More information: www.bbs-artebone.fi